Last reviewed · How we verify
Regadenoson myocardial perfusion imaging
Regadenoson myocardial perfusion imaging is a Adenosine A2A receptor agonist Small molecule drug developed by University of Colorado, Denver. It is currently FDA-approved for Myocardial perfusion imaging in patients unable to exercise or requiring pharmacologic stress testing. Also known as: Cardiolite (sestamibi), Regadenoson (Lexiscan).
Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to detect areas of reduced perfusion during cardiac imaging.
Regadenoson is a selective adenosine A2A receptor agonist that increases coronary blood flow to detect areas of reduced perfusion during cardiac imaging. Used for Myocardial perfusion imaging in patients unable to exercise or requiring pharmacologic stress testing.
At a glance
| Generic name | Regadenoson myocardial perfusion imaging |
|---|---|
| Also known as | Cardiolite (sestamibi), Regadenoson (Lexiscan) |
| Sponsor | University of Colorado, Denver |
| Drug class | Adenosine A2A receptor agonist |
| Target | Adenosine A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Regadenoson binds to adenosine A2A receptors on coronary vascular smooth muscle, causing vasodilation and increasing blood flow preferentially to normally perfused myocardium. This creates a differential in blood flow between healthy and ischemic regions, allowing visualization of perfusion defects on imaging. It is used as a pharmacologic stress agent as an alternative to exercise stress testing in myocardial perfusion imaging studies.
Approved indications
- Myocardial perfusion imaging in patients unable to exercise or requiring pharmacologic stress testing
Common side effects
- Dyspnea
- Chest discomfort
- Headache
- Flushing
- Palpitations
- Dizziness
Key clinical trials
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study (NA)
- Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
- The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (NA)
- Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (PHASE2)
- Allograft Dysfunction in Heart Transplant (PHASE4)
- Regadenoson R-T Perfusion Imaging Trial (PHASE1)
- A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT) (PHASE2)
- Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regadenoson myocardial perfusion imaging CI brief — competitive landscape report
- Regadenoson myocardial perfusion imaging updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI
Frequently asked questions about Regadenoson myocardial perfusion imaging
What is Regadenoson myocardial perfusion imaging?
How does Regadenoson myocardial perfusion imaging work?
What is Regadenoson myocardial perfusion imaging used for?
Who makes Regadenoson myocardial perfusion imaging?
Is Regadenoson myocardial perfusion imaging also known as anything else?
What drug class is Regadenoson myocardial perfusion imaging in?
What development phase is Regadenoson myocardial perfusion imaging in?
What are the side effects of Regadenoson myocardial perfusion imaging?
What does Regadenoson myocardial perfusion imaging target?
Related
- Drug class: All Adenosine A2A receptor agonist drugs
- Target: All drugs targeting Adenosine A2A receptor
- Manufacturer: University of Colorado, Denver — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Myocardial perfusion imaging in patients unable to exercise or requiring pharmacologic stress testing
- Also known as: Cardiolite (sestamibi), Regadenoson (Lexiscan)
- Compare: Regadenoson myocardial perfusion imaging vs similar drugs
- Pricing: Regadenoson myocardial perfusion imaging cost, discount & access